166 related articles for article (PubMed ID: 33073300)
1. Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.
Chen J; Wang W; Sun H; Pang L; Yin B
J Comput Aided Mol Des; 2020 Dec; 34(12):1289-1305. PubMed ID: 33073300
[TBL] [Abstract][Full Text] [Related]
2. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
Chuang YC; Huang BY; Chang HW; Yang CN
Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
[TBL] [Abstract][Full Text] [Related]
3. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
4. Drug-resistance mechanisms of three mutations in anaplastic lymphoma kinase against two inhibitors based on MM/PBSA combined with interaction entropy.
Xiao Z; Cong Y; Huang K; Zhong S; Zhang JZH; Duan L
Phys Chem Chem Phys; 2019 Oct; 21(37):20951-20964. PubMed ID: 31524891
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
Goyal S; Jamal S; Shanker A; Grover A
J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
[TBL] [Abstract][Full Text] [Related]
7. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.
Sun HY; Ji FQ
Biochem Biophys Res Commun; 2012 Jun; 423(2):319-24. PubMed ID: 22659414
[TBL] [Abstract][Full Text] [Related]
8. Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase.
Kumar A; Shanthi V; Ramanathan K
Mol Inform; 2015 Feb; 34(2-3):105-14. PubMed ID: 27490033
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
10. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Wu X; Wang Y; Wan S; Zhang J
J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
[TBL] [Abstract][Full Text] [Related]
11. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
[TBL] [Abstract][Full Text] [Related]
12. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
He MY; Li WK; Zheng QC; Zhang HX
ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
[TBL] [Abstract][Full Text] [Related]
13. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Shaw AT; Friboulet L; Leshchiner I; Gainor JF; Bergqvist S; Brooun A; Burke BJ; Deng YL; Liu W; Dardaei L; Frias RL; Schultz KR; Logan J; James LP; Smeal T; Timofeevski S; Katayama R; Iafrate AJ; Le L; McTigue M; Getz G; Johnson TW; Engelman JA
N Engl J Med; 2016 Jan; 374(1):54-61. PubMed ID: 26698910
[TBL] [Abstract][Full Text] [Related]
14. A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.
He M; Li W; Zheng Q; Zhang H
J Cell Biochem; 2018 Jul; 119(7):5332-5342. PubMed ID: 29323742
[TBL] [Abstract][Full Text] [Related]
15. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
16. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.
Sun H; Li Y; Li D; Hou T
J Chem Inf Model; 2013 Sep; 53(9):2376-89. PubMed ID: 23952683
[TBL] [Abstract][Full Text] [Related]
17. Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach.
Kumar A; Ramanathan K
J Mol Model; 2014 Jul; 20(7):2324. PubMed ID: 24952065
[TBL] [Abstract][Full Text] [Related]
18. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
19. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
Ni Z; Zhang TC
J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
[TBL] [Abstract][Full Text] [Related]
20. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
